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low-level radiation (LLR) exposures retard the develop-
ment of neoplasms in humans and experimental animals. 
Here, we review immunosuppressive mechanisms induced 
by growing tumors as well as immunomodulatory effects 
of LLR evidently or likely associated with cancer-inhibit-
ing outcomes of such exposures. We also offer suggestions 
how LLR may restore and/or stimulate effective anti-tumor 
immunity during the more advanced stages of carcinogene-
sis. We postulate that, based on epidemiological and exper-
imental data amassed over the last few decades, whole- or 
half-body irradiations with LLR should be systematically 
examined for its potential to be a viable immunotherapeutic 
treatment option for patients with systemic cancer.
Keywords Low-level radiation · Carcinogenesis · 
Immune suppression · Radio-immunotherapy
Abbreviations
ADCC  Antibody-dependent cellular cytotoxicity
DAMP  Damage-associated molecular pattern
Gy  Gray (the SI unit of absorbed dose defined as 
the absorption of 1 J of the radiation energy 
per 1 kg of matter)
HBI  Half-body irradiation
HMGB1  High-mobility group box 1 protein
IR  Ionizing radiation
LET  Linear energy transfer
LLR  Low-level radiation
LNT  Linear, no threshold
M1, M2  Macrophage phenotypes 1 and 2
MC  Mast cell
mGy  Milligray (0.001 Gy)
N1, N2  Neutrophil phenotypes 1 and 2
NHL  Non-Hodgkin’s lymphoma
NKG2DL  Ligand for the natural killer group 2D receptor
Abstract The cancer immunoediting hypothesis assumes 
that the immune system guards the host against the incipi-
ent cancer, but also “edits” the immunogenicity of sur-
viving neoplastic cells and supports remodeling of tumor 
microenvironment towards an immunosuppressive and 
pro-neoplastic state. Local irradiation of tumors during 
standard radiotherapy, by killing neoplastic cells and gen-
erating inflammation, stimulates anti-cancer immunity and/
or partially reverses cancer-promoting immunosuppres-
sion. These effects are induced by moderate (0.1–2.0 Gy) 
or high (>2  Gy) doses of ionizing radiation which can 
also harm normal tissues, impede immune functions, and 
increase the risk of secondary neoplasms. In contrast, such 
complications do not occur with exposures to low doses 
(≤0.1  Gy for acute irradiation or ≤0.1  mGy/min dose 
rate for chronic exposures) of low-LET ionizing radiation. 
Furthermore, considerable evidence indicates that such 
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NKT  Natural killer T lymphocyte
NOD  Nucleotide-binding oligomerization domain
PGE2  Prostaglandin E2
RT  Radiotherapy
Th  Helper T lymphocyte
Treg  Regulatory T lymphocyte
VEGF  Vascular endothelial growth factor
WBI  Whole-body irradiation
Introduction
The immune system is a crucial player in the organism’s 
control over the development of neoplasms (reviewed in 
[1]). After years of controversies, the early concept of can-
cer immunological surveillance [2, 3], whereby specifically 
stimulated (adaptive) immunity wards off proliferation 
of neoplastically transformed cells, has now been incor-
porated into the modern cancer immunoediting process. 
During the three phases of this process, the anti-neoplas-
tic immune functions and immunogenicity of cancer cells 
are being gradually “edited”, so that the immune system 
protects the host against the development of a malignancy 
during the initial “elimination” phase, but later, during the 
following “equilibrium” and, especially, “escape” phases, 
morphs into an active supporter of cancer progression. 
Consequently, the emerging tumor not only evades immune 
recognition and destruction, but also actively contributes to 
remodeling of its microenvironment towards the immuno-
suppressive and pro-neoplastic state [4–10].
The improved understanding of the relationship between 
a growing tumor and the immune system has shed new light 
on the recently acknowledged complex interactions of ion-
izing radiation (IR) with cancer-related immunity. This, in 
turn, has led to the development of novel radiotherapeutic 
schemes based on the notion that local exposures at moder-
ate (between 0.1 and 2.0 Gy absorbed during acute expo-
sures) or even high doses (over 2.0  Gy) of radiation can, 
especially in combination with standard immunotherapy, 
stimulate various anti-neoplastic immune reactions, and/
or reverse their suppressive state. These effects are thought 
to result from the radiation-induced immunogenic types of 
cell death, local inflammation, and tissue injury, all leading 
to the emergence of “danger signals” which prompt activi-
ties of the non-specific (innate) immune system; extensive 
recapitulation of the immunomodulatory effects of local 
radiotherapy (RT) has recently been summarized in a num-
ber of excellent reviews [11–20]. However, even moderate 
radiotherapeutic doses are potentially harmful to the sur-
rounding normal tissues, which can cause immunosuppres-
sion and/or induce secondary cancers [21–23]. Such com-
plications are highly unlikely after exposures to low doses 
(≤0.1 Gy absorbed within a short time or ≤0.1 mGy/min 
dose rate applied during a protracted exposure) of low lin-
ear energy transfer (LET) IR, referred to in this paper as 
low-level radiation (LLR). Indeed, the effects of exposures 
to LLR, including modulation of the immune functions, can 
qualitatively and quantitatively differ from those induced 
by moderate-to-high doses of low-LET radiation [24–29].
The present paper indentifies and evaluates epidemio-
logical as well as animal studies which indicate that expo-
sures to LLR can inhibit or retard the development of pri-
mary and metastatic cancers [27, 30–91]. This evaluation 
will include an assessment of possible mechanisms by 
which such protective effects may be mediated including: 
LLR-induced scavenging of reactive chemical intermedi-
ates, stimulation of the repair of the DNA damage, mitiga-
tion of inflammation, triggering of selective apoptosis or 
senescence of aberrant cells, and the up-regulation of both 
the innate and adaptive arms of the anti-cancer immune 
system [25, 92–95]. Since enhancing anti-neoplastic immu-
nity may be an important mechanism of the cancer-inhib-
itory effects of LLR [93–101], clinical trials of whole- or 
half-body irradiations (WBI or HBI) with LLR are also 
evaluated [102–106].
This paper will also assess how LLR can affect and 
modify advanced phases of cancer development resulting 
in a reversal of suppressed immune functions and/or resto-
ration of the susceptibility of cancer cells to the assaults by 
immune effectors. However, in contrast to the extensively 
reviewed relations between moderate- and high-dose RT 
and the response of the immune system, recapitulations of 
the similar effects of LLR in the context of their clinical 
exploitation are virtually nonexistent. The present paper 
will complement and extend a recent review of the vast pre-
clinical evidence of the LLR-induced protective/adaptive 
response in normal but not neoplastic tissues, which pro-
vides arguments for the trials of the LLR-based therapy of 
cancer [29].
Immunosuppressive tumor microenvironment
The concept that in vertebrates, elements of the immune 
system specifically recognize and eliminate incipient neo-
plastic cells and protect thereby against the development of 
overt malignancy dates back to late 1950s [2, 3]. In accord-
ance with this “cancer immunosurveillance” hypothesis, it 
was demonstrated that both immuno-compromised human 
patients and experimental animals are at increased risk of 
developing various neoplasms (reviewed in [107]). How-
ever, investigations by Stutman showed that chemically 
induced sarcomas or adenomas do not develop more often 
in athymic, T-cell-deficient, nude mice than in their wide-
type, immunocompetent counterparts [108]. This observa-
tion seriously challenged the cancer immunosurveillance 
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model and almost led to its abandonment [7]. Yet, evidence 
accumulated in recent years has helped to explain what 
was wrong with the original cancer immunosurveillance 
hypothesis and why some neoplasms progress to their clini-
cal stage. Thus, it was found that innate immunity initially 
senses the presence of transformed cells and exercises the 
first line of anti-cancer defense. Soon after the activation, 
elements of the innate immune system promote induc-
tion of adaptive (specific) anti-tumor responses. However, 
owing to genetic and epigenetic changes in the developing 
neoplastic cells, tumors may become “invisible” to immune 
effectors through loss or aberrant expression of the MHC 
class I antigens (reviewed in [109, 110]) or of other mol-
ecules on cancer cells involved in triggering of the innate 
and/or adaptive immune responses [111, 112]. For exam-
ple, a change in hydrophobicity of tumor cells may lead to 
suppressed expression of the “damage-associated molecular 
pattern” (DAMP) molecules necessary to alert the innate 
immune system to a “danger” incurred by the presence of 
aberrant cells [113]. Notably, even the “danger signals”, 
such as high-mobility group box 1 protein (HMGB1), can 
actually support cancer growth through stimulation of mye-
loid-derived suppressor cells (MDSCs) [114] or nurse-like 
cells [115] that create conditions favorable for cancer pro-
gression. Furthermore, tumor-associated specific antigens 
may assume forms similar to those expressed on normal 
cells and evade recognition as “non-self” by the immune 
system (reviewed in [116]).
Developing tumors create microenvironments that not 
only support neoplastic growth and metastasis, but also sig-
nificantly reduce the effectiveness and corrupt the functions 
of both the innate and adaptive arms of anti-cancer immu-
nity [10]. Among the immunosuppressive components 
of tumor microenvironments are various soluble factors 
such as IL-10, TGF-β, vascular endothelial growth factor 
(VEGF), prostaglandin E2  (PGE2), HMGB1, indoleamine-
2,3-dioxygenase (IDO), as well as soluble forms of phos-
phatidylserine, Fas receptors, and MHC class I-related 
chain A proteins (reviewed in [117, 118]). Another recently 
recognized immunosuppressive mechanism involves the 
activation of the so-called immune checkpoints whose 
function is to prevent overstimulation of the immune system 
(reviewed in [119, 120]). The two most important immune 
checkpoint co-inhibitory molecules likely to play a role 
in induction and maintenance of the immunosuppressive 
state within tumors are members of the immunoglobulin 
gene superfamily, the cytotoxic T lymphocyte-associated 
antigen 4 (CTLA-4) whose expression on T helper cells 
suppresses the activity of cytolytic  CD8+ T lymphocytes, 
and the programmed death 1 (PD-1; CD279) receptor pri-
marily expressed on tumor-infiltrating lymphocytes (TILs) 
and monocytes which, upon combining with its respec-
tive ligands (PDL-1 and PDL-2), negatively regulates the 
anti-neoplastic function of T cells [121, 122]; in addition, 
the PD-1:PDL-1 interaction may promote the development 
and function of regulatory T (Treg) cells [123].
Active immunosuppression is also exerted by many 
non-specific and specific cellular effectors residing in or 
attracted to neoplastic tissue. Many different cells capable 
of inhibiting anti-cancer immunity and promoting can-
cer growth have now been identified. These include Treg 
lymphocytes [125, 126], MDSCs [127–130], macrophages 
[128, 131–133], natural killer T (NKT) [134–136], Th17 
[137–139] and B lymphocytes [140–143], but also neu-
trophils [131, 144–147], dendritic cells (DCs) [148–151], 
mast cells (MCs) [152], and mesenchymal stem cells 
[153–155].
It has been finally well established that persistent acti-
vation of pro-inflammatory immunity facilitates cellular 
transformation and promotes tumor advancement. Unlike 
acute transient inflammatory responses which attract and 
activate elements of the innate immune system, chronic 
inflammation not only supports cancer progression, but also 
prevents the host from mounting effective immune defenses 
against it [129, 156–162]. An intermediate role in this pro-
cess of the inflammation-driven type 2 immune response is 
played by MDSCs which are attracted to inflammatory sites 
and facilitate tumor growth [163, 164]. Chronic inflamma-
tion, as a powerful driver of carcinogenesis, is associated 
with aberrant signaling mediated by the nucleotide-binding 
oligomerization domain (NOD)-like receptors expressed 
on DCs, macrophages, and lymphocytes [165, 166]. Criti-
cal immunosuppressive mechanisms operating in the tumor 
microenvironment during the advanced stages of carcino-
genesis are outlined in Fig. 1.
Anti-neoplastic and immunomodulatory effects 
of LLR
Overview
The development and progression of cancer in both humans 
and laboratory animals can be suppressed or prevented by 
exposures to LLR. The results of about 40 epidemiological 
studies published since 1987 have demonstrated decreased 
or unaltered cancer incidence or mortality rates in human 
populations exposed to LLR during medical diagnos-
tic tests and therapy, in the course of professional activi-
ties, or as residents of geographical areas and homes with 
elevated levels of natural background radiation (evidence 
presented in Supplementary Table  1). Likewise, between 
1996 and 2014, at least 27 reports were published from 
controlled experiments carried out in mice, rats, and dogs, 
as well as in cultured cells demonstrating that single, mul-
tiple, or chronic irradiations with LLR exert anti-neoplastic 
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activities and markedly inhibit the growth and/or advance-
ment of spontaneous or induced tumors (evidence pre-
sented in Supplementary Table  2). In general, the results 
of both epidemiological and experimental studies indicate 
or suggest that, in the case of short-term exposures at a 
high-dose rate, the upper threshold for the control of tumor 
growth is around 0.1 Gy [25, 61–63, 71, 167–169]. As evi-
denced by the results of experimental studies conducted in 
the in vivo and in vitro systems, one of the most important 
underlying mechanisms of such tumor-inhibitory effects 
is up-regulation of both the innate and adaptive immu-
nity. Numerous reports published between 1988 and 2014 
indicate that exposures to LLR are potent stimulators of 
various anti-neoplastic functions of the immune system, 
including inhibition of inflammation and/or up-regulation 
of anti-inflammatory cytokines (evidence presented in Sup-
plementary Table 3 and reviewed in [74, 80, 94, 170, 171]).
Specific studies demonstrating anti-tumor effects 
by LLR
There are also a number of reports dating back to early 
1980s which demonstrate association of the LLR-induced 
up-regulation of anti-neoplastic immunity with inhibition 
of cancer development:
1. In 1982, Robert Anderson and collaborators [172] were 
among the first to report retardation of the growth of 
transplanted tumors in A/J mice following WBI with 
X-rays at doses ranging from 0.005 to 0.025 Gy imme-
diately prior to s.c. inoculation of Sarcoma I cells. The 
evidence clearly suggested the involvement of “a very 
radiosensitive T cell with suppressor activity”.
2. In 1994, Kharazi et  al. showed that chronic low-dose 
WBI with γ-rays (0.04 Gy per exposure, three times per 
Fig. 1  Tumor microenviron-
ment during the late stages of 
cancer development: Immu-
nosuppressive influences. B 
B lymphocytes, CD8+  CD8+ 
T lymphocytes, HMGB1 
high-mobility group box 1 
protein, IDO indoleamine-
2,3-dioxygenase, M1 phenotype 
1 macrophages, M2 phenotype 
2 macrophages, N1 phenotype 
1 neutrophils, N2 phenotype 2 
neutrophils, Treg regulatory T 
lymphocytes, NKG2DL ligand 
for the natural killer group 2D 
receptor, NKG2D natural killer 
group 2D receptor, VEGF vas-
cular endothelial growth factor
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week for 4 weeks) when combined with caloric restric-
tion enhanced the regression of mammary tumors 
spontaneously developing in female C3H/He mice. 
These tumors were massively infiltrated with cytotoxic 
 CD8+ T cells. Such tumor regression did not occur in 
mice subjected to caloric restriction alone [173].
3. As reported in 1999 by Hashimoto et  al., a single 
WBI at 0.2 Gy of γ-rays of WKHA rats injected with 
hepatoma cells led to a significant reduction in the 
number of lung and lymph node metastases accom-
panied by the markedly stimulated influx of  CD8+ 
lymphocytes into the spleen and the tumor site along 
with the enhanced expression of mRNAs for IFN-γ 
and TNF-α and down-regulation of mRNA for TGF-
β; no mRNAs for IL-4, IL-6, and IL-10, the Th2-type 
cytokines that inhibit the anti-tumor Th1 responses, 
were detected in these tissues [69].
4. The studies by Yu et al. showed that a single exposure 
of male Kunming mice (a strain similar to C57BL/6 
mice) to 0.075  Gy X-rays 6  h before implantation 
of S180 sarcoma cells significantly inhibited tumor 
growth accompanied by the influx of TILs as well as 
enhanced necrosis and down-regulation of the expres-
sion of receptors for VEGF in the neoplastic tissue [73, 
74].
5. Continuous irradiation of C57BL/6 mice with γ-rays at 
1.2 mGy/h for 258 days (up to 7.2 Gy total dose) did 
not induce thymic lymphomas, whereas the same total 
dose absorbed during four acute exposures to X-rays at 
1.8  Gy resulted in the appearance of the lymphomas 
in 90% of these animals; in the continuously irradi-
ated mice, the numbers of  CD4+ T cells and antibody-
producing B cells were significantly enhanced in the 
spleen [75].
6. Continuous exposure to γ-rays of the lymphoma-prone 
SJL/J mice at 100 mGy/y dose rate slightly prolonged 
life span of the animals and the effect was accompa-
nied by the significant increase in the percentages of 
 CD49+ NK cells and decreased percentages of  CD4+ 
and  CD8+ lymphocytes in the spleen [174]. When 
spleens of rats with a diethylnitrosamine-induced liver 
cancer were irradiated at 0.15  Gy from the 6  MeV 
β-beam accelerator at 100 mGy/min dose rate, the per-
centage of  CD4+CD25+ Treg cells in the blood signifi-
cantly decreased and the levels of Foxp3, IL-10, TGF-
β, and CTLA-4 were down-regulated in the spleen and 
the tumor; these changes were accompanied by the 
suppressed tumor growth [175].
7. Experimental combinations of low-level WBI with the 
conventional (intermediate- or high-dose) local RT also 
yielded promising results: using murine tumor mod-
els of B16 melanoma and Lewis lung carcinoma, Liu 
and collaborators demonstrated that when fractionated 
local X-ray irradiations of the tumors at 2 Gy/fraction 
were several times substituted for WBI at 0.075 Gy, the 
cancer control (as judged by the reduced tumor mass 
and pulmonary metastases as well as by the increased 
survival of the hosts) was significantly improved com-
pared to local RT alone; this effect was accompanied 
by up-regulation of the activities of the splenic NK 
and cytotoxic T lymphocytes which secreted elevated 
amounts of IFN-γ and TNF-α [77, 78].
Our strategies showing anti-tumor effects by LLR
In a series of our own experiments carried out in the rela-
tively radiosensitive BALB/c mice and the relatively radi-
oresistant C57BL/6 mice, both single and multiple WBI 
with X-rays at total doses ranging from 0.05 to 0.2  Gy 
reproducibly suppressed development of the induced neo-
plastic colonies in the lungs. Since the mice were whole-
body irradiated before inoculation of the syngeneic tumor 
cells, the obvious suggestion was that the low-level X-ray 
exposures stimulated systemic innate anti-neoplastic reac-
tions. Although we were not able to directly estimate the 
activities of immune cells in the lungs, a significant stimu-
lation of the cytotoxic activities of NK cells and LPS- and 
IFN-γ-stimulated macrophages obtained from the spleen 
and peritoneal cavity, respectively, was detected in the 
X-ray-exposed mice from both strains. Interestingly, no ele-
vation of the activities of these cells was detected after their 
in vitro irradiation at the same doses of X-rays indicating 
that enhancing of the NK- and macrophage-mediated cyto-
lytic functions by LLR depends on the presence of factors 
occurring in in vivo but not the in vitro conditions [81–90, 
176–179].
Clinical trials
The above-described epidemiological and experimental 
observations of anti-neoplastic and immunomodulatory 
effects of LLR exposures provide grounds for clinical trials 
with WBI or HBI of oncological patients [101, 180]. Even 
before the aforementioned evidence gained significance, a 
few LLR-based therapy trials had been performed. In 1965, 
Holder reported on positive therapeutic effects of the low-
level total-body irradiation of patients with multiple mye-
loma [181]. In 1975, Kazem described curative effects of 
WBI (0.15 Gy of γ-rays daily for the first 5 days and there-
after at 0.1–0.15 Gy every other day or at longer intervals 
to the total doses of 2.0–2.65 Gy applied over 5–12 weeks) 
of patients with disseminated stage III lymphomas [182]. 
Likewise, Chaffey et al. obtained complete remissions in 32 
out of 40 patients with advanced lymphocytic lymphoma 
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after repeated WBI (0.15 Gy twice a week to a total dose 
of 1.5  Gy) as an initial and only primary therapy [102]. 
Very promising results of low-level total-body exposures 
to γ-rays of patients with non-Hodgkin’s lymphoma (NHL) 
were also reported by Qasim [183] and Choi et  al. [103]. 
In one of the later trials, 24 out of 26 patients with stage 
IV low grade NHL were in complete remission after two 
courses of low-dose, total-body irradiation at 0.75 Gy given 
in five fractions; when the initially pathological lymph 
node areas of these patients were 1 month later treated with 
the conventional RT (total dose of 40  Gy applied in 20 
fractions), the disease remitted in yet another patient [184]. 
Similarly, Safwat et al. who used low-level total-body expo-
sures (0.1–0.25 Gy several times a week to the total dose of 
1.5–2.0 Gy) obtained complete remissions in 11 out of 35 
patients and 2-year progression-free survival in 12 patients 
with relapsed and/or chemo-resistant NHL; in 14 patients, 
a significant increase in the percentage of  CD4+ T cells in 
the blood was noted [105]. In addition, as demonstrated by 
Sakamoto et  al., low-dose HBI with X-rays (0.1–0.15  Gy 
two times a week for 5  weeks) combined with local RT 
(2 Gy five times a week for 6 weeks) resulted in the 5-year 
survival of 84% of patients with stage I and II NHL as com-
pared to 65% survival of patients treated solely with local 
RT (the difference significant at p < 0.05); in these patients, 
percentages of peripheral blood  CD4+ T helper lympho-
cytes were significantly elevated [100].
While more clinical trials employing WBI or HBI with 
LLR are needed, they are hampered by radiation safety 
regulations based on the linear, no threshold (LNT) model 
of the dose–effect relationship assuming that any absorbed 
dose of radiation causes a finite increase in cancer risk. 
There is a growing consensus that the LNT hypothesis 
lacks a solid experimental foundation and is based largely 
on ideology rather than science [25, 169, 185–193]. Hope-
fully, the many recent appeals from radiobiologists, phy-
sicians, and health physicists to various regulatory bodies 
and authorities to base the radiation protection system on 
scientific data indicating that there are quantitative and 
qualitative differences between the effects of low doses 
delivered at low dose rates and high doses delivered at 
high-dose rates [171, 187, 188, 190, 192, 194, 195] will 
lead to a revision of current radiation protection regula-
tions, so that WBI with LLR can be tested in clinical trials.
Suggested effects of LLR on cancer immunoediting 
process
As reviewed above, both acute and chronic exposures to 
LLR stimulate various anti-neoplastic immune reactions 
that are stifled or corrupted within the tumor microenviron-
ment, especially during the later stages of carcinogenesis. 
Based on evidence indicating that tumor-inhibiting effects 
of LLR have been observed in both humans and experi-
mental animals exposed in many different ways to sin-
gle, multiple, and chronic irradiation with LLR, it may be 
argued that many, if not all, of the above-reviewed tumor-
promoting immune mechanisms are likely to be blocked 
and/or reversed by such exposures (Fig.  2). Indeed, data 
indicating that LLR exposures may reverse the tumor-asso-
ciated immune suppression has recently begun to emerge, 
even though many underlying LLR-induced mechanisms 
remain to be clarified. Based on the current evidence it 
may be postulated that, in addition to the direct activation 
of NK lymphocytes [83, 196, 197] and possibly other anti-
tumor cytotoxic cells, LLR exposures enhance the “vis-
ibility” and/or susceptibility of cancer cells to immune 
assaults through stimulation of the expression by neoplastic 
and immune cells of molecules and ligands (e.g., CD2, B7, 
CD28, NKG2D) necessary for triggering of cytotoxic reac-
tions [198–200] and/or turning on “danger signals” in the 
neoplastic tissue [201, 202]. Furthermore, low-level radia-
tion exposures are likely to alleviate or reverse the tumor-
associated immune degeneracy through elimination or 
inhibition of the multiple cells, cytokines, and other factors 
associated with immunosuppressive loops induced by the 
tumor [175, 203–207]. This could result in: (a) shifting of 
the immune response in favor of the anti-neoplastic pheno-
types such as Th1 in the case of  CD4+ T cells [97, 208], M1 
in the case of macrophages [209, 210], and N1 in the case 
of neutrophils [211], (b) targeting the Treg-Th17 and Th17-
DC interactions conducive to tumor regression [212–214], 
(c) activation of the Toll-like receptor-mediated signaling 
in phagocytes and antigen-presenting cells [215–217], (d) 
attenuation of the chronic inflammation pertinent to cancer 
initiation, promotion, and progression [94, 95, 170, 218, 
219], and/or (e) down-regulation of the immune checkpoint 
molecules such as the CTLA-4, PD-1, and/or PD-L1 on 
T cells [198, 220–222]. Indeed, one of the recent reports 
indicates that hypofractionated γ-ray irradiation of tumors 
induced in C57BL/6 mice combined with blockade of the 
PD-1 checkpoint stimulated accumulation of TILs associ-
ated with complete eradication of very large neoplasms 
[222]. In addition, there are numerous non-immune mecha-
nisms triggered by LLR that positively affect normal, but 
not malignant cells [29]. These include: (a) increased cell 
proliferation, (b) stimulation of anti-oxidant reactions asso-
ciated with the reduction of tissue injury, (c) improved 
repair of the DNA damage, and (d) metabolic shift from 
oxidative phosphorylation to aerobic glycolysis resulting in 
increased radioresistance of healthy tissues. Such outcomes 
are of primary importance for the combination of the LLR-
based immunotherapy with classic forms of cancer ther-
apy (i.e., high-dose RT and chemotherapy) that are lethal 
to normal cells and tissues and promote the formation of 
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reactive oxygen species and inflammation. It is expected 
that other LLR-triggered reactions and mechanisms will 
be detected providing additional grounds for the use of the 
truly low-level exposures to IR in the treatment of cancer 
and, possibly, other diseases.
Conclusion and prospects
Cancer immunotherapy has matured from the application 
of several therapeutic agents, including tumor cell- and 
dendritic cell-based vaccines, anti-cytokine antibodies, 
checkpoint inhibitors, and genetically engineered T cells 
and stem cells, which collectively act to reverse immune 
suppression in the tumor environment and/or immune 
resistance of tumor cells (reviewed in [208]). There are 
also clinical trials combining such agents with local irra-
diation of tumors at moderate doses (i.e., >0.5–1.0  Gy 
per fraction) currently used in RT [16]. The recently 
acknowledged capacity of locally applied moderate or 
high (radiotherapeutic) doses of radiation to induce 
immunogenic death of cancer cells and local inflamma-
tory reactions associated with stimulation of dendritic 
cells and enhancing the suppressed anti-cancer immu-
nity has been employed as an adjuvant to improve the 
efficacy of existing immunotherapy protocols (reviewed 
in [11–19, 21]). However, such exposures can also cause 
persistent inflammation and multiple cell death in normal 
tissues, impede various immune and other physiologi-
cal functions, and increase the risk of secondary primary 
cancers. In contrast, LLR exposures do not kill or impair 
and actually support functions of normal cells and tis-
sues, selectively eliminate precancerous and transformed 
cells, attenuate rather than induce chronic inflammation, 
stimulate various anti-neoplastic reactions of the immune 
system, and are not associated with the development of 
secondary malignancies [21, 29, 94, 95, 170]. Finally, as 
indicated by the above-reviewed results of experimental 
and epidemiological studies as well as several clinical tri-
als, WBI or HBI with LLR are not likely to induce any 
Fig. 2  LLR-induced immune-
related mechanisms mediat-
ing anti-neoplastic effects: 
Proposed framework. ADCC 
antibody-dependent cellular 
cytotoxicity, B B lymphocytes, 
CD8+  CD8+ T lymphocytes, 
DAMPs damage-associated 
molecular pattern molecules, 
HMGB1 high-mobility group 
box 1 protein, M1 phenotype 
1 macrophages, M2 phenotype 
2 macrophages, N1 phenotype 
1 neutrophils, N2 phenotype 2 
neutrophils, Treg regulatory T 
lymphocytes, NKG2DL ligand 
for the natural killer group 2D 
receptor, NKG2D natural killer 
group 2D receptor, VEGF vas-
cular endothelial growth factor
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untoward side effects and can thus be used in treatment of 
patients with systemic or metastatic cancer.
It is, therefore, time to employ whole- or half-body 
exposures to LLR (alone or as an adjuvant to conventional 
therapeutics) to restore the efficacy of systemic anti-cancer 
functions of the immune system, the most potent guardian 
against neoplasia. This approach is expected to mediate 
improved clinical responses in cancer patients, as well as 
protect normal tissues from the well-known adverse effects 
associated with standard chemo- and radiotherapy used in 
contemporary cancer therapeutics.
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